Emerging 2026 Research Is Pointing to a New Root Cause of High Blood Pressure on TRT — and What Can Finally Be Done About It
I've been treating men on testosterone whose cuff and lipid panel keep climbing for twenty years. For most of those twenty years, the field didn't have a clear answer for what was causing it.
That's changed.
Over the last several years, a body of research has been building across cardiology, endocrinology, and blood-clotting journals — and in 2026, what was once a fringe hypothesis is becoming the broadly accepted explanation: the blood pressure and cholesterol that climb on TRT are, at their core, a condition of thick blood and the fibrin scaffold it lets build.
You don't need to take my word for it. Open a new tab and type "testosterone therapy and blood pressure" into Google. Look at what comes up.
Medical journals. Research universities. Clinical reviews. This isn't fringe. It's where the science has landed.
Here's what that actually means.
What The Fibrin Scaffold Is
Right inside your arteries, there's a living, ever-shifting mesh called the fibrin scaffold. Think of it as the steel frame of a building going up, but alive, and laid along every artery, every vein, and every tiny vessel in your body, holding every patch in place.
When you're young and your blood runs thin and fast, it's put up and torn down within hours. Your blood rushes past it without dragging. You don't feel it. It does its job invisibly.
But that scaffold needs fast blood and clean-up enzymes to stay that way — the flow and fibrin-eaters it uses to come down on time, keep the channel wide, and keep nothing stuck to it.
On testosterone, that clean-up slows down. Your body builds more red cells every week and your blood turns to syrup. Twice-weekly pins, a hematocrit of 54, stress, and accumulated wear speed the process up. The scaffold stops getting torn down.
So it builds up.
A scaffold that never comes down loses its thin, temporary quality. It hardens. It grabs. And as it grabs, it begins to physically catch everything that flows past it — including the small, dense LDL your testosterone has been making.
And once you understand that mechanism, every symptom you've been carrying makes sense.
The cuff that keeps reading higher
Fibrin lines your vessels from head to toe. When the scaffold builds in thick, slow blood across that many arteries at once, your home cuff reads 138, then 142, then 146 — because the entire system is under pressure.
The "fine" panel that isn't
The scaffold lining the arteries of your heart catches the small, dense LDL testosterone makes. When it builds, your total reads fine while the plaque doesn't.
The pulse pounding in your ear
When the scaffold thickens inside the arteries of your neck and head, every heartbeat has to shove harder. You lie in bed hearing your own pulse thump because the blood is being forced through a channel narrower than it should be.
Doing the math on 51
When the scaffold is built, every heartbeat costs more than it should. By 1am, you're reading stroke abstracts not because you're paranoid — but because your heart has been pushing syrup against resistance from the inside.
The Research Behind It
This isn't a single study or a fringe theory. It's a converging body of work across multiple labs and journals:
Testosterone given to men shrank their LDL particles into the smaller, denser kind in just three weeks — and lowered HDL with it.
In 5,246 men on testosterone, heart attacks didn't rise — but blood clots in the lungs and atrial fibrillation did.
Eight weeks of nattokinase brought down both systolic and diastolic blood pressure in people whose readings ran high.
Across six randomized trials and 546 people, nattokinase cut systolic pressure by 3.45 points and diastolic by 2.32.
These are a few papers out of dozens. All peer-reviewed, all in PubMed, all published in major medical journals.
The 2023 meta-analysis is the most recent — and it confirms, in six randomized trials, that nattokinase lowers the pressure thick blood drives up.
The findings are public. They've just been slow to reach clinical practice.
Why Nothing You've Tried Has Worked
Donating blood, cutting your dose, a statin — every fix your clinic has handed you for your TRT bloodwork is designed to do the same thing: drain, cut, or lower one number on the sheet.
None of them touch the reason your pressure and your plaque are climbing in the first place. The fibrin scaffold is still there, still catching every particle that flows past, still squeezing the channel your heart is pushing syrup through.
That's why the numbers always creep back. Nothing in your medicine cabinet was ever pointed at the scaffold.
What Tearing Down The Scaffold Actually Requires
It's the same mechanism, in reverse.
Your scaffold built up because thick blood outran the enzyme that tears it down. Give that enzyme back at the dose that works, and the fibrin dissolves. As it dissolves, the artery opens. As it opens, it releases its grip on the blood your heart is pushing — and the cuff, the panel, and the 1am math start to resolve at the source.
There's no shortcut around this. You can't drain enough blood, or cut your dose far enough, to fix a problem that lives inside the artery wall. The scaffold has to be cleared from the inside, with the enzyme your blood can't keep up with.
I spent years recommending the closest things I could find — baby aspirin, fish oil, 4,000 FU nattokinase off a forum list. I kept coming back to the same conclusion: the ingredients existed, but nothing was putting them together correctly.
So in early 2025, I decided to build the formulation myself.
I teamed up with a small group of hormone and blood-clotting researchers, and we spent the better part of a year working through the literature, sourcing the right forms of each ingredient, and testing the formulation. By the end of 2025, we had it.
Noverly Nattokinase
The formulation centers on three core actives — chosen because they're each in the form that actually reaches the scaffold.
They're supported by CoQ10, bromelain, turmeric, pine bark, grape seed, and dandelion root — a matrix that helps the actives absorb and reach the artery wall.
Every ingredient is research-backed. Every dose is based on what the peer-reviewed literature supports. Nothing is in there for marketing — no 4,000 FU half-dose, no fillers, no ingredients that look impressive on a label but don't reach the artery wall.
What Happened With The First 1,000 Customers
In early 2026 we ran an initial launch and tracked outcomes from our first 1,000 customers across the first 90 days on the protocol. Among those who completed the full 90 days:
These aren't clinical trial numbers. They're self-reported outcomes from real customers — most of whom had been fighting their TRT blood pressure and cholesterol for over two years and had already tried everything else.
Most reported the shift starting between week three and week six. By day 90, the majority were describing it the same way: not numbers they had bought with a lower dose, but numbers that moved while they kept every milligram.
If you've been managing your TRT bloodwork long enough to know that draining a pint isn't the same as clearing the scaffold, Noverly is built for what you've actually been looking for.
Try it for 90 days.
If it doesn't work for you in that window, send it back. Full refund. No questions, no fine print, no return process designed to wear you down. I don't want patients paying for something that isn't helping them.